WO2000023417A1 - Nouveaux composes, leur preparation et leur utilisation - Google Patents
Nouveaux composes, leur preparation et leur utilisation Download PDFInfo
- Publication number
- WO2000023417A1 WO2000023417A1 PCT/DK1999/000574 DK9900574W WO0023417A1 WO 2000023417 A1 WO2000023417 A1 WO 2000023417A1 DK 9900574 W DK9900574 W DK 9900574W WO 0023417 A1 WO0023417 A1 WO 0023417A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ethoxy
- phenyl
- dibenzo
- cyclohepten
- propionic acid
- Prior art date
Links
- 0 **C(C1=C(*2)C=CCC=CC=C1)c1c2c(*)c(*)c(*)c1* Chemical compound **C(C1=C(*2)C=CCC=CC=C1)c1c2c(*)c(*)c(*)c1* 0.000 description 1
- IYHXUFMFSRQULX-UHFFFAOYSA-N CCOC(Cc(cc1)ccc1OCCOC1c(cccc2)c2SCc2ccccc12)C(OCC)=O Chemical compound CCOC(Cc(cc1)ccc1OCCOC1c(cccc2)c2SCc2ccccc12)C(OCC)=O IYHXUFMFSRQULX-UHFFFAOYSA-N 0.000 description 1
- SUTDFDKTEDJWJO-UHFFFAOYSA-N CCOC(Cc(cc1)ccc1OCCOC1c2ccccc2CCc2ccccc12)C(OCC)=O Chemical compound CCOC(Cc(cc1)ccc1OCCOC1c2ccccc2CCc2ccccc12)C(OCC)=O SUTDFDKTEDJWJO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/12—Eight-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D337/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99950504A EP1123269A1 (fr) | 1998-10-21 | 1999-10-19 | Nouveaux composes, leur preparation et leur utilisation |
AU63258/99A AU6325899A (en) | 1998-10-21 | 1999-10-19 | New compounds, their preparation and use |
JP2000577145A JP2002527503A (ja) | 1998-10-21 | 1999-10-19 | 新規化合物類、それらの調製及び使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199801356 | 1998-10-21 | ||
DKPA199801356 | 1998-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000023417A1 true WO2000023417A1 (fr) | 2000-04-27 |
Family
ID=8103962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1999/000574 WO2000023417A1 (fr) | 1998-10-21 | 1999-10-19 | Nouveaux composes, leur preparation et leur utilisation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1123269A1 (fr) |
JP (1) | JP2002527503A (fr) |
AU (1) | AU6325899A (fr) |
WO (1) | WO2000023417A1 (fr) |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035437A2 (fr) * | 1998-12-17 | 2000-06-22 | Mindset Biopharmaceuticals (Usa), Inc. | Utilisation accrue de glucose par le cerveau |
WO2003031432A1 (fr) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Nouvelles piperidines substituees |
WO2003055482A1 (fr) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Derives amide utiles en tant qu'activateurs de la glucokinase |
WO2004002481A1 (fr) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Activateurs de la glycokinase |
WO2004101505A1 (fr) | 2003-05-14 | 2004-11-25 | Novo Nordisk A/S | Nouveaux composes pour le traitement de l'obesite |
WO2005030797A2 (fr) | 2003-09-30 | 2005-04-07 | Novo Nordisk A/S | Nouveaux agonistes du recepteur de la melanocortine |
WO2005105785A2 (fr) | 2004-05-04 | 2005-11-10 | Novo Nordisk A/S | Nouveaux derives d'indole |
EP1634605A2 (fr) | 2000-03-08 | 2006-03-15 | Novo Nordisk A/S | Traitement de la dyslipidémie chez un patient souffrant de diabète de type 2 |
US7015345B2 (en) | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
US7041837B2 (en) | 2001-07-26 | 2006-05-09 | Cadilla Healthcare Limited | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine |
WO2006053906A1 (fr) | 2004-11-22 | 2006-05-26 | Novo Nordisk A/S | Formulations solubles stables contenant de l'insuline et un sel de protamine |
WO2006058923A1 (fr) | 2004-12-03 | 2006-06-08 | Novo Nordisk A/S | Composés hétéroaromatiques activants de glucokinase |
WO2007006814A1 (fr) | 2005-07-14 | 2007-01-18 | Novo Nordisk A/S | Activateurs de l'uree glucokinase |
WO2007015805A1 (fr) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | Composés joints en position 1-amino |
WO2007110364A1 (fr) | 2006-03-28 | 2007-10-04 | High Point Pharmaceuticals, Llc | Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine |
WO2007123581A1 (fr) | 2005-11-17 | 2007-11-01 | Eli Lilly And Company | Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques |
WO2007137968A1 (fr) | 2006-05-29 | 2007-12-06 | High Point Pharmaceuticals, Llc | Benzodioxolylcyclopropylpipérazinylpyridazines |
WO2008059025A1 (fr) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Nouvelles 2-(2-hydroxyphényl) benzothiadiazines utilisées pour traiter l'obésité et le diabète |
WO2008059026A1 (fr) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Nouveaux 2-(2-hydroxyphényl)benzimidazoles utilisés pour traiter l'obésité et le diabète |
WO2008084044A1 (fr) | 2007-01-11 | 2008-07-17 | Novo Nordisk A/S | Activateurs de l'urée glucokinase |
EP2154131A1 (fr) * | 2007-04-26 | 2010-02-17 | Pharmafrontier, Co., Ltd. | Inhibiteur du récepteur couplé à protéine g et produit pharmaceutique |
WO2010047982A1 (fr) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques |
WO2010051206A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques |
EP2233470A1 (fr) | 2005-07-04 | 2010-09-29 | High Point Pharmaceuticals, LLC | Antagonists du receptor histamine H3 |
EP2298337A2 (fr) | 2003-12-09 | 2011-03-23 | Novo Nordisk A/S | Régulation des préférences alimentaires en utilisant des agonistes du GLP-1 |
EP2305352A1 (fr) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques |
EP2316446A1 (fr) | 2004-06-11 | 2011-05-04 | Novo Nordisk A/S | Remède contre l'obésité induite par les médicaments au moyen d'agonistes GLP-1 |
WO2011069038A2 (fr) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonistes de la guanylate cyclase utiles dans le traitement de l'hypercholestérolémie, de l'athérosclérose, d'une coronaropathie, des calculs biliaires, de l'obésité et d'autres maladies cardiovasculaires |
WO2011104379A1 (fr) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides pour le traitement de l'obésité |
WO2011106273A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques |
WO2011104378A1 (fr) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides de traitement de l'obésité |
WO2011117415A1 (fr) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Nouveaux analogues du glucagon |
WO2012027331A1 (fr) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés |
EP2444397A1 (fr) | 2004-01-06 | 2012-04-25 | Novo Nordisk A/S | Hétéroaryl-urées et leur utilisation en tant qu'activateurs de glucokinase |
WO2012104869A1 (fr) | 2011-01-31 | 2012-08-09 | Cadila Healthcare Limited | Traitement de la lipodystrophie |
WO2012116145A1 (fr) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
WO2012130866A1 (fr) | 2011-03-28 | 2012-10-04 | Novo Nordisk A/S | Nouveaux analogues de glucagon |
WO2013082106A1 (fr) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Différenciation en adipocytes bruns |
WO2013138352A1 (fr) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation |
US8541368B2 (en) | 2011-09-23 | 2013-09-24 | Novo Nordisk A/S | Glucagon analogues |
WO2014022528A1 (fr) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
WO2014130608A1 (fr) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
WO2014151200A2 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
WO2014151206A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
EP2810951A2 (fr) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
WO2014197720A2 (fr) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation |
WO2015001573A1 (fr) | 2013-07-05 | 2015-01-08 | Cadila Healthcare Limited | Compositions synergiques |
WO2015051725A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
EP2998314A1 (fr) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
US9474790B2 (en) | 2013-04-18 | 2016-10-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
EP3241839A1 (fr) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
US9814697B2 (en) | 2013-04-22 | 2017-11-14 | Cadila Healthcare Limited | Composition for nonalcoholic fatty liver disease (NAFLD) |
WO2018106518A1 (fr) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
WO2018118670A1 (fr) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
WO2018167194A1 (fr) | 2017-03-15 | 2018-09-20 | Novo Nordisk A/S | Composés bicycliques aptes à se lier au récepteur de mélanocortine 4 |
US10098868B2 (en) | 2013-07-25 | 2018-10-16 | Cadila Healthcare Limited | Formula comprising a hypolipidemic agent |
US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
US10130684B2 (en) | 2011-02-03 | 2018-11-20 | Pharmedica Ltd. | Oral dissolving films for insulin administration, for treating diabetes |
US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
US10435363B2 (en) | 2013-05-30 | 2019-10-08 | Cadila Healthcare Limited | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
WO2019219714A1 (fr) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Composés capables de se lier au récepteur de la mélanocortine 4 |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
WO2020053414A1 (fr) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4 |
US11433050B2 (en) | 2016-12-09 | 2022-09-06 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004261A1 (fr) * | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Benzoxoazoles et derives de pryridine destines a etre utilises pour le traitement du diabete tardif |
WO1997025042A1 (fr) * | 1996-01-09 | 1997-07-17 | Smithkline Beecham P.L.C. | Utilisation d'un agoniste de ppar-alpha et de ppar-gamma dans le traitement du syndrome x |
WO1997036579A1 (fr) * | 1996-03-30 | 1997-10-09 | Glaxo Group Limited | Utilisation d'agonistes du recepteur alpha active par un proliferateur de peroxysome pour traiter l'obesite |
JPH10182550A (ja) * | 1996-12-25 | 1998-07-07 | Mitsui Chem Inc | ヒドロキシ安息香酸誘導体およびそれを有効成分として含有する医薬品 |
WO1999019313A1 (fr) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant |
-
1999
- 1999-10-19 JP JP2000577145A patent/JP2002527503A/ja active Pending
- 1999-10-19 EP EP99950504A patent/EP1123269A1/fr not_active Withdrawn
- 1999-10-19 AU AU63258/99A patent/AU6325899A/en not_active Abandoned
- 1999-10-19 WO PCT/DK1999/000574 patent/WO2000023417A1/fr not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004261A1 (fr) * | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Benzoxoazoles et derives de pryridine destines a etre utilises pour le traitement du diabete tardif |
WO1996004260A1 (fr) * | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Benzoxazoles et derives de pyridine utiles dans le traitement du diabete de type ii |
WO1997025042A1 (fr) * | 1996-01-09 | 1997-07-17 | Smithkline Beecham P.L.C. | Utilisation d'un agoniste de ppar-alpha et de ppar-gamma dans le traitement du syndrome x |
WO1997036579A1 (fr) * | 1996-03-30 | 1997-10-09 | Glaxo Group Limited | Utilisation d'agonistes du recepteur alpha active par un proliferateur de peroxysome pour traiter l'obesite |
JPH10182550A (ja) * | 1996-12-25 | 1998-07-07 | Mitsui Chem Inc | ヒドロキシ安息香酸誘導体およびそれを有効成分として含有する医薬品 |
WO1999019313A1 (fr) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant |
Non-Patent Citations (1)
Title |
---|
DATABASE CAPLUS, [online] FUKAZAWA NOBUYUKI ET AL.: "Preparation of hydroxybenzoic acids, their use as cell adhesion inhibitors and their pharmaceutical compositions", XP002946707, retrieved from 129:108904 accession no. STN International, File CAPLUS Database accession no. 1998:430714 * |
Cited By (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035437A3 (fr) * | 1998-12-17 | 2000-11-09 | Mindset Biopharmaceuticals Usa | Utilisation accrue de glucose par le cerveau |
WO2000035437A2 (fr) * | 1998-12-17 | 2000-06-22 | Mindset Biopharmaceuticals (Usa), Inc. | Utilisation accrue de glucose par le cerveau |
EP1634605A2 (fr) | 2000-03-08 | 2006-03-15 | Novo Nordisk A/S | Traitement de la dyslipidémie chez un patient souffrant de diabète de type 2 |
US7323491B2 (en) | 2001-07-26 | 2008-01-29 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
US8110598B2 (en) | 2001-07-26 | 2012-02-07 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
US8558009B2 (en) | 2001-07-26 | 2013-10-15 | Cadila Healthcare Limited | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
US7041837B2 (en) | 2001-07-26 | 2006-05-09 | Cadilla Healthcare Limited | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine |
WO2003031432A1 (fr) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Nouvelles piperidines substituees |
EP2243776A1 (fr) | 2001-10-12 | 2010-10-27 | High Point Pharmaceuticals, LLC | Piperidines substituées et leur utilisation dans le traitement de maladies liées au recepteur histaminique H3 |
WO2003055482A1 (fr) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Derives amide utiles en tant qu'activateurs de la glucokinase |
EP2305648A1 (fr) | 2001-12-21 | 2011-04-06 | Novo Nordisk A/S | Dérivés d'amide en tant qu'activateurs de la glucokinase |
US7015345B2 (en) | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
EP2471533A1 (fr) | 2002-06-27 | 2012-07-04 | Novo Nordisk A/S | Dérivés d'aryle carbonyle en tant qu'agents thérapeutiques |
WO2004002481A1 (fr) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Activateurs de la glycokinase |
WO2004101505A1 (fr) | 2003-05-14 | 2004-11-25 | Novo Nordisk A/S | Nouveaux composes pour le traitement de l'obesite |
WO2005030797A2 (fr) | 2003-09-30 | 2005-04-07 | Novo Nordisk A/S | Nouveaux agonistes du recepteur de la melanocortine |
EP2298337A2 (fr) | 2003-12-09 | 2011-03-23 | Novo Nordisk A/S | Régulation des préférences alimentaires en utilisant des agonistes du GLP-1 |
EP2444397A1 (fr) | 2004-01-06 | 2012-04-25 | Novo Nordisk A/S | Hétéroaryl-urées et leur utilisation en tant qu'activateurs de glucokinase |
EP2305352A1 (fr) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques |
WO2005105785A2 (fr) | 2004-05-04 | 2005-11-10 | Novo Nordisk A/S | Nouveaux derives d'indole |
EP2316446A1 (fr) | 2004-06-11 | 2011-05-04 | Novo Nordisk A/S | Remède contre l'obésité induite par les médicaments au moyen d'agonistes GLP-1 |
WO2006053906A1 (fr) | 2004-11-22 | 2006-05-26 | Novo Nordisk A/S | Formulations solubles stables contenant de l'insuline et un sel de protamine |
WO2006058923A1 (fr) | 2004-12-03 | 2006-06-08 | Novo Nordisk A/S | Composés hétéroaromatiques activants de glucokinase |
EP2386554A1 (fr) | 2005-07-04 | 2011-11-16 | High Point Pharmaceuticals, LLC | Composés actives sur le recepteur histamine H3 |
EP2233470A1 (fr) | 2005-07-04 | 2010-09-29 | High Point Pharmaceuticals, LLC | Antagonists du receptor histamine H3 |
WO2007006814A1 (fr) | 2005-07-14 | 2007-01-18 | Novo Nordisk A/S | Activateurs de l'uree glucokinase |
EP2377856A1 (fr) | 2005-07-14 | 2011-10-19 | Novo Nordisk A/S | Activateurs de la glucokinase d'urée |
WO2007015805A1 (fr) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | Composés joints en position 1-amino |
WO2007123581A1 (fr) | 2005-11-17 | 2007-11-01 | Eli Lilly And Company | Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques |
WO2007110364A1 (fr) | 2006-03-28 | 2007-10-04 | High Point Pharmaceuticals, Llc | Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine |
WO2007137968A1 (fr) | 2006-05-29 | 2007-12-06 | High Point Pharmaceuticals, Llc | Benzodioxolylcyclopropylpipérazinylpyridazines |
EP2402324A1 (fr) | 2006-05-29 | 2012-01-04 | High Point Pharmaceuticals, LLC | Benzodioxolylcyclopropylpipérazinylpyridazines |
WO2008059026A1 (fr) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Nouveaux 2-(2-hydroxyphényl)benzimidazoles utilisés pour traiter l'obésité et le diabète |
WO2008059025A1 (fr) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Nouvelles 2-(2-hydroxyphényl) benzothiadiazines utilisées pour traiter l'obésité et le diabète |
WO2008084044A1 (fr) | 2007-01-11 | 2008-07-17 | Novo Nordisk A/S | Activateurs de l'urée glucokinase |
EP2154131A1 (fr) * | 2007-04-26 | 2010-02-17 | Pharmafrontier, Co., Ltd. | Inhibiteur du récepteur couplé à protéine g et produit pharmaceutique |
EP2154131A4 (fr) * | 2007-04-26 | 2011-09-21 | Pharmafrontier Co Ltd | Inhibiteur du récepteur couplé à protéine g et produit pharmaceutique |
EP2998314A1 (fr) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
EP2810951A2 (fr) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
EP3241839A1 (fr) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
WO2010047982A1 (fr) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques |
WO2010051206A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques |
EP2923706A1 (fr) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de l'hypercholestérolémie |
WO2011069038A2 (fr) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonistes de la guanylate cyclase utiles dans le traitement de l'hypercholestérolémie, de l'athérosclérose, d'une coronaropathie, des calculs biliaires, de l'obésité et d'autres maladies cardiovasculaires |
WO2011106273A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques |
WO2011104378A1 (fr) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides de traitement de l'obésité |
WO2011104379A1 (fr) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides pour le traitement de l'obésité |
WO2011117415A1 (fr) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Nouveaux analogues du glucagon |
WO2011117416A1 (fr) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Nouveaux analogues du glucagon |
WO2012027331A1 (fr) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés |
US10017470B2 (en) | 2011-01-31 | 2018-07-10 | Cadila Healthcare Limited | Treatment for lipodystrophy |
WO2012104869A1 (fr) | 2011-01-31 | 2012-08-09 | Cadila Healthcare Limited | Traitement de la lipodystrophie |
US9783495B2 (en) | 2011-01-31 | 2017-10-10 | Cadila Healthcare Limited | Treatment for lipodystrophy |
EP3009136A1 (fr) | 2011-01-31 | 2016-04-20 | Cadila Healthcare Limited | Traitement de la lipodystrophie |
US10130684B2 (en) | 2011-02-03 | 2018-11-20 | Pharmedica Ltd. | Oral dissolving films for insulin administration, for treating diabetes |
WO2012116145A1 (fr) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
EP3243385A1 (fr) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
WO2012130866A1 (fr) | 2011-03-28 | 2012-10-04 | Novo Nordisk A/S | Nouveaux analogues de glucagon |
US8541368B2 (en) | 2011-09-23 | 2013-09-24 | Novo Nordisk A/S | Glucagon analogues |
US9486505B2 (en) | 2011-09-23 | 2016-11-08 | Novo Nordisk A/S | Glucagon analogues |
WO2013082106A1 (fr) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Différenciation en adipocytes bruns |
WO2013138352A1 (fr) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation |
EP3708179A1 (fr) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation |
EP4309673A2 (fr) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation |
WO2014022528A1 (fr) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
WO2014130608A1 (fr) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
WO2014151206A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
WO2014151200A2 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
US9474790B2 (en) | 2013-04-18 | 2016-10-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
US9751927B2 (en) | 2013-04-18 | 2017-09-05 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
US9814697B2 (en) | 2013-04-22 | 2017-11-14 | Cadila Healthcare Limited | Composition for nonalcoholic fatty liver disease (NAFLD) |
US10435363B2 (en) | 2013-05-30 | 2019-10-08 | Cadila Healthcare Limited | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
WO2014197720A2 (fr) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation |
US9957230B2 (en) | 2013-07-05 | 2018-05-01 | Cadila Healthcare Limited | Synergistic compositions |
US9656954B2 (en) | 2013-07-05 | 2017-05-23 | Cadila Healthcare Limited | Synergistic compositions |
EP3120845A1 (fr) | 2013-07-05 | 2017-01-25 | Cadila Healthcare Limited | Compositions synergiques |
WO2015001573A1 (fr) | 2013-07-05 | 2015-01-08 | Cadila Healthcare Limited | Compositions synergiques |
US10315993B2 (en) | 2013-07-05 | 2019-06-11 | Cadila Healthcare Limited | Synergistic compositions |
US10098868B2 (en) | 2013-07-25 | 2018-10-16 | Cadila Healthcare Limited | Formula comprising a hypolipidemic agent |
US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
WO2015051725A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
WO2018106518A1 (fr) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
US11433050B2 (en) | 2016-12-09 | 2022-09-06 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
US11872209B2 (en) | 2016-12-09 | 2024-01-16 | Zydus Lifesciences Limited | Treatment for primary biliary cholangitis |
WO2018118670A1 (fr) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
WO2018167194A1 (fr) | 2017-03-15 | 2018-09-20 | Novo Nordisk A/S | Composés bicycliques aptes à se lier au récepteur de mélanocortine 4 |
WO2019219714A1 (fr) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Composés capables de se lier au récepteur de la mélanocortine 4 |
WO2020053414A1 (fr) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4 |
Also Published As
Publication number | Publication date |
---|---|
AU6325899A (en) | 2000-05-08 |
JP2002527503A (ja) | 2002-08-27 |
EP1123269A1 (fr) | 2001-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6353018B1 (en) | Compounds, their preparation and use | |
EP1123269A1 (fr) | Nouveaux composes, leur preparation et leur utilisation | |
WO2000023416A1 (fr) | Nouveaux composes, leur preparation et leur utilisation | |
WO2000023425A1 (fr) | Nouveaux composes, preparation et utilisation correspondantes | |
US6534517B2 (en) | Compounds, their preparation and use | |
EP1123297A1 (fr) | Nouveaux composes, leur preparation et leur utilisation | |
EP1123292A1 (fr) | Nouveaux composes, leur preparation et leur utilisation | |
EP1171431A1 (fr) | Composes, leur preparation et utilisation | |
US6602901B2 (en) | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | |
US6468996B1 (en) | Substituted hetero-polycyclic compounds as PPARα and PPARγ activators | |
US6525086B2 (en) | Compounds, their preparation and use | |
US6300339B1 (en) | Compounds, their preparation and use | |
US6703401B2 (en) | Compounds, their preparation and use | |
US6369055B1 (en) | Compounds, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 63258 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999950504 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 577145 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1999950504 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999950504 Country of ref document: EP |